



OPEN ACCESS

EDITED BY
Pathology & Oncology Research
Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Zhi-Gang Yao,
yzg20062009@163.com
Miao-Qing Zhao,
zhaomqs@163.com

†These authors have contributed equally
to this work

RECEIVED 04 December 2022
ACCEPTED 12 January 2023
PUBLISHED 30 January 2023

CITATION
Ma Y-T, Li Y, Yan L, Hua F, Wang D-G,
Xu G-Y, Yang H-L, Xue Y-J, Qin Y-J,
Sha D, Ning H, Zhao M-Q and Yao Z-G
(2023), Corrigendum: Case report:
Potential predictive value of MMR/MSI
status and PD-1 expression in
immunotherapy for
urothelial carcinoma.
Pathol. Oncol. Res. 29:1610989.
doi: 10.3389/pore.2023.1610989

COPYRIGHT
© 2023 Ma, Li, Yan, Hua, Wang, Xu,
Yang, Xue, Qin, Sha, Ning, Zhao and Yao.
This is an open-access article
distributed under the terms of the
Creative Commons Attribution License
(CC BY). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma

Yu-Ting Ma^{1†}, Yan Li^{2†}, Li Yan^{3†}, Fang Hua⁴, Dong-Guan Wang³,
Guo-Ying Xu⁵, Hong-Lan Yang², Ying-Jie Xue¹, Ye-Jun Qin¹,
Dan Sha⁶, Hao Ning⁷, Miao-Qing Zhao^{8*} and Zhi-Gang Yao ^{1*}

¹Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, ²Department of Oncology, Dongying City People's Hospital, Dongying, China, ³Department of Pathology, Dongying City People's Hospital, Dongying, China, ⁴Department of Microbiology and Immunology, Tulane University, New Orleans, LA, United States, ⁵Department of Urology Surgery, Dongying Hospital of Traditional Chinese Medicine, Dongying, China, ⁶Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, ⁷Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, ⁸Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China

KEYWORDS

immunotherapy, microsatellite instability, immune checkpoint inhibitors, urothelial carcinoma, lynch syndrome, PD-1/PD-L1

A Corrigendum on Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma

by Ma Y-T, Li Y, Yan L, Hua F, Wang D-G, Xu G-Y, Yang H-L, Xue Y-J, Qin Y-J, Sha D, Ning H, Zhao M-Q and Yao Z-G (2022). *Pathol Oncol Res.* 28:1610638. doi: 10.3389/pore.2022.1610638

In the published article there was an error in the author list. Authors Hong-Lan Yang and Yan Li were listed in the wrong order. The equal contribution of the first co-authors was not included. The corrected author list appears below:

Yu-Ting Ma^{1†}, Yan Li^{2†}, Li Yan^{3†}, Fang Hua⁴, Dong-Guan Wang³, Guo-Ying Xu⁵, Hong-Lan Yang², Ying-Jie Xue¹, Ye-Jun Qin¹, Dan Sha⁶, Hao Ning⁷, Miao-Qing Zhao^{8*} and Zhi-Gang Yao^{1*†}

[†]ORCID: Zhi-Gang Yao, orcid.org/0000-0002-8034-6524

^{*}Contributed equally to this work

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.